pharma · Breast Cancer · Multiple Sclerosis (MS)
HOFFMANN-LA ROCHE
Hoffmann-La Roche
Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo
Company details
- Status
- Public
- HQ
- Mississauga, Ontario L5N 5M8, CA
- Employees
- 10
- Programs
- 286
- Drugs
- 212
- Patents
- 0
BX44273
Phase 3 · small molecule · This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
BX44273 for This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Internal code BX44273
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
- Status
- active
- Trials
- 1